US/UK/Canada

Share

Contacts

  • Sprint Bioscience
    NOVUM 141 57 Huddinge Sweden
    +46-8-411 44 55
    http://www.sprintbioscience.com

    • Quotes

    Inhibiting TREX1 is a unique approach with great potential to enhance the effect of several current therapies. Many modern cancer drugs depend on the immune system being able to identify the cancer cells, and with our TREX1 inhibitors, we have identified a way to stop the cancer cells' ability to hide from the immune system. We have now reached a strong competitive position in the program's development and look forward to discussions with potential partners.
    Martin Andersson, head of research at Sprint Bioscience
    We have once again been able to identify a target protein that constitutes a very attractive starting point for a new drug program. The ambition is to influence the microenvironment of the tumors so that the growth of cancer cells is inhibited and the body's immune system can more easily fight them. We will in a time- and resource-efficient way drive the project to a point where it can dock into an international pharmaceutical company's portfolio and be taken further to clinic development towards the market and cancer patients who need new treatment option
    Erik Kinnman, CEO, Sprint Bioscience
    Immunotherapy is showing tremendous benefits in cancer but unfortunately the majority of cancer patients do not respond to current immunotherapy approaches. There is therefore a great need to increase the tumor’s susceptibility of attack from the immune system, and here inhibitors of the protein Vps34 may play an important role.
    Dr. Ravi Amaravadi, MD Associate Professor of Medicine and Sprint Bioscience scientific advisor,
    We thank Anders Åberg for all the fantastic work that has led to Sprint Bioscience becoming the high-quality company it is today.
    Rune Nordlander, Chairman of Sprint Bioscience
    We are very happy to have entered into this agreement with LG Chem Life Sciences Company, a perfect partner to further develop this program.
    Dr. Anders Åberg, CEO of Sprint Bioscience
    Leveraging Sprint Bioscience’s expertise in fragment-based drug discovery capability and LG Chem Life Sciences’ capability in pharma-ceutical development, we aim to accelerate bringing new treatment options for NASH and metabolic syndrome.
    Dr. Jeewoong Son, President of LG Chem Life Sciences Company
    Patent protection gives us an edge over others in the field
    Anders Åberg, CEO, Sprint Bioscience
    We know from our contacts with the pharmaceutical industry that immuno-oncology is an area where demand for new projects is high
    Anne-Marie Wenthzel, Head of Business Development at Sprint Bioscience
    We are really happy to have closed a deal with a company with world leading expertise in tumor metabolism biology. It will increase the chances to develop a drug to the benefit for cancer patients.
    Dr Anders Åberg, CEO of Sprint Bioscience
    To combine frontline research with our platform for fast and resource efficient development of drugs, together with the Lundberg Laboratory for Diabetes Research, provides great opportunities for Sprint Bioscience to develop a new cure for T2D
    Dr Anders Åberg, CEO Sprint Bioscience
    I look forward to working with Sprint Bioscience in this project. Together, we will develop inhibitors that affect a central mechanism for insulin resistance
    Dr Margit Mahlapuu, The Lundberg Laboratory for Diabetes Research
    We are very happy to have entered into this agreement for one of our tumor metabolism projects. We are convinced that Bayer is a perfect partner to further develop this program.
    Anders Åberg, CEO, Sprint Bioscience
    We are looking forward to expanding our portfolio in this area through the agreement with Sprint Bioscience. This early research program has the potential to lead to new treatment options for cancer patients.
    Professor Andreas Busch, Head of Global Drug Discovery and member of the Executive Committee of Bayer HealthCare
    Pick a time period -
    Tags ( Active)
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Rss